×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Roivant Sciences: Executing On Huge Buyback Program With More To Come (NASDAQ:ROIV)
Seeking Alpha
Roivant Sciences' stock is undervalued and it holds stakes in biotech companies worth billions, including Immunovant and Arbutus.
3 days ago
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Yahoo Finance
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25.
6 days ago
Rafferty Asset Management LLC Increases Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)
MarketBeat
Rafferty Asset Management LLC boosted its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 25.1% during the 4th quarter,...
17 hours ago
Roivant Sciences Ltd. (ROIV) Tops Q4 EPS by 9c
StreetInsider
Roivant Sciences Ltd. (NASDAQ: ROIV) reported Q4 EPS of ($0.19), $0.09 better than the analyst estimate of ($0.28).
6 days ago
Capstone Investment Advisors LLC Takes $170000 Position in Roivant Sciences Ltd. (NASDAQ:ROIV)
Defense World
Read Capstone Investment Advisors LLC Takes $170000 Position in Roivant Sciences Ltd. (NASDAQ:ROIV) at Defense World.
1 day ago
Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2023 Earnings Call Transcript
Insider Monkey
Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2023 Earnings Call Transcript May 30, 2024. Operator: Good day and thank you for standing by.
5 days ago
Roivant Sciences share maintains price target, Overweight on Q4 results By Investing.com
Investing.com
On Friday, Piper Sandler reiterated its Overweight rating on Roivant Sciences (NASDAQ:ROIV) with a steady stock price target of $20.00.
5 days ago
ROIV Stock Quote Price and Forecast
CNN
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes...
2 months ago
Roivant's CEO is a star, but even a blockbuster deal can't escape biotech's black hole
STAT
The company's Matt Gline created $5 billion from $50 million — in less than one year. And yet Roivant's stock still traded down.
7 months ago
Roivant Sciences (ROIV) Shares Cross Below 200 DMA
Nasdaq
In trading on Thursday, shares of Roivant Sciences Ltd (Symbol: ROIV) crossed below their 200 day moving average of $10.62, changing hands...
6 days ago